501 related articles for article (PubMed ID: 24319222)
1. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies.
Landgren O
Hematology Am Soc Hematol Educ Program; 2013; 2013():478-87. PubMed ID: 24319222
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies.
Korde N; Kristinsson SY; Landgren O
Blood; 2011 May; 117(21):5573-81. PubMed ID: 21441462
[TBL] [Abstract][Full Text] [Related]
3. [The pathology of smoldering multiple myeloma].
Shibayama H
Nihon Rinsho; 2015 Jan; 73(1):33-7. PubMed ID: 25626300
[TBL] [Abstract][Full Text] [Related]
4. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
Golombick T; Diamond TH; Manoharan A; Ramakrishna R
Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
[TBL] [Abstract][Full Text] [Related]
5. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
Mateos MV; Landgren O
Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
8. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.
Agarwal A; Ghobrial IM
Clin Cancer Res; 2013 Mar; 19(5):985-94. PubMed ID: 23224402
[TBL] [Abstract][Full Text] [Related]
10. Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
Chang SH; Gumbel J; Luo S; Thomas TS; Sanfilippo KM; Luo J; Colditz GA; Carson KR
Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2055-2061. PubMed ID: 31501149
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
González-Calle V; Mateos MV
Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
[TBL] [Abstract][Full Text] [Related]
12. [Smoldering multiple myeloma].
Fouquet G; Guidez S; Herbaux C; Demarquette H; Leleu X
Rev Med Interne; 2014 Apr; 35(4):243-9. PubMed ID: 24050785
[TBL] [Abstract][Full Text] [Related]
13. Multiple myeloma precursor disease.
Landgren O; Waxman AJ
JAMA; 2010 Dec; 304(21):2397-404. PubMed ID: 21119086
[TBL] [Abstract][Full Text] [Related]
14. Treatment of high-risk smoldering myeloma.
Korde N
Semin Oncol; 2016 Dec; 43(6):695-696. PubMed ID: 28061988
[TBL] [Abstract][Full Text] [Related]
15. Development of early treatment strategies for high-risk myeloma precursor disease in the future.
Landgren O; Rajkumar SV
Semin Hematol; 2011 Jan; 48(1):66-72. PubMed ID: 21232660
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
Hillengass J; Moehler T; Hundemer M
Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma.
Schmidt T; Callander N
J Natl Compr Canc Netw; 2020 Dec; 18(12):1720-1729. PubMed ID: 33347744
[TBL] [Abstract][Full Text] [Related]
18. Progress in the Management of Smoldering Multiple Myeloma.
Schmidt TM; Callander NS
Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
[TBL] [Abstract][Full Text] [Related]
19. Asymptomatic and Treatment-requiring Multiple Myeloma - Data from the Czech Registry of Monoclonal Gammopathies.
Brozova L; Jarkovský J; Pour L; Minárik J; Jungová A; Gregora E; Spicka I; Maisnar V; Hájek R
Klin Onkol; 2017; 30(Supplementum2):51-59. PubMed ID: 28903571
[TBL] [Abstract][Full Text] [Related]
20. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.
Musto P; Engelhardt M; Caers J; Bolli N; Kaiser M; Van de Donk N; Terpos E; Broijl A; De Larrea CF; Gay F; Goldschmidt H; Hajek R; Vangsted AJ; Zamagni E; Zweegman S; Cavo M; Dimopoulos M; Einsele H; Ludwig H; Barosi G; Boccadoro M; Mateos MV; Sonneveld P; Miguel JS
Haematologica; 2021 Nov; 106(11):2799-2812. PubMed ID: 34261295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
